Minnelide (injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily) leads to a marked decrease in tumor weight and volume at the end of treatment and increases survival in orthotopic model of pancreatic cancer with MIA PaCa-2–derived human pancreatic tumors[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg; once daily; 28 days) prevents locoregional spread and leads to a decrease in average tumor weight in a xenograft model of pancreatic cancer with metastatic S2-013 cells[2].
Minnelide (injection intraperitoneally; 0.42 mg/kg, 0.21 mg/kg; once daily) causes tumor regression and tumors from Minnelide-treated animals showed fibrosis and the presence of pyknotic nuclei in human pancreatic cancer xenografts in SCID mice[2].
| Animal Model: | Orthotopic model of pancreatic cancer with MIA PaCa 2-derived human pancreatic tumors in athymic nude mice[2] |
| Dosage: | 0.1-0.6 mg/kg |
| Administration: | Injection intraperitoneally; 0.1-0.6 mg/kg; once daily or twice daily |
| Result: | Prevented pancreatic tumor growth in vivo. |
| Animal Model: | Xenograft model of pancreatic cancer with metastatic S2-013 cell line in athymic nude mice[2] |
| Dosage: | 0.42 mg/kg |
| Administration: | Injection intraperitoneally; 0.42 mg/kg; once daily |
| Result: | Prevented extensive spread from the primary site of injection. |
| Animal Model: | Human pancreatic cancer xenografts in SCID mice[2] |
| Dosage: | 0.21 mg/kg, 0.42 mg/kg |
| Administration: | Injection intraperitoneally; 0.42 mg/kg; once daily |
| Result: | Reduced tumor burden in human xenografts from patients. |
![Trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-8b-methyl-6a-(1-methylethyl)-6-[(phosphonooxy)methoxy]-, sodium salt (1:2), (3bS,4aS,5aR,6R,6aS,7aS,7bS,8aS,8bS)- Structure](/CAS/20211123/GIF/1254702-87-8.gif)
